On May 4, 2022, Prof. Dr. Kiat Rakrungtham Director of Project Management for COVID-19 Vaccine Development Project, Vaccine Research Center Faculty of Medicine Chulalongkorn University Talking about the progress of the development of the ChulaCov19 mRNA vaccine, Thai nationality, that the first phase was to design a vaccine and have the factory in the United States produce the first lot. safe It stimulates the immune system to be highly satisfactory. Compared to the Pfizer vaccine approved for use in Thailand, the immune system is clearly higher.
The second development phase is the domestic production of vaccines by Bionet Asia Company Limited, a factory in Thailand. The first batch of vaccines was already produced. passed quality assurance The research team has submitted various documents and information to the Food and Drug Administration (FDA) to request testing in phase 1 and 2 subjects, pending approval by the FDA. Expect to receive a response soon if Tested according to the set goals should be able to apply for vaccine registration by the end of 2022
Prof. Dr. Kiat continued that the epidemic situation in the country is now getting better. But vaccine development has not stopped. Therefore, I would like to see 3 types of first generation vaccines produced by Thai people that are currently being developed, namely the mRNA vaccine of Chulalongkorn University, the drug leaf vaccine and the Government Pharmaceutical Organization vaccine If you can register first for one type or all of them, the better. The first batch of vaccines according to the procedure should be registered first. Proven to be safe During the application for registration, the second generation was developed to prevent Omicron at the same time. to wait for the next registration